Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Today, 7:20 AMLarimar reported a third-quarter 2026 net loss of $31.1 million, or $0.29 per share, and $128.7 million in cash with runway into late Q2 2027.
Index
RUT
Market Cap
322.04M
Enterprise Value
170.73M
Income
-172.60M
Sales
0.00M
Book/sh
1.22
Cash/sh
1.50
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
71
IPO
Jun 19, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.54
P/C
2.06
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
4.70
Current Ratio
4.70
Debt/Eq
0.04
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-1.98
EPS next Y
-1.14
EPS next Q
-0.35
EPS this Y
39.40%
EPS next Y
17.24%
EPS next 5Y
29.36%
EPS past 3/5Y
-18.15% 8.74%
Sales past 3/5Y
- -
EPS Y/Y TTM
-27.00%
Sales Y/Y TTM
-
EPS Q/Q
23.18%
Sales Q/Q
-
Insider Own
54.01%
Insider Trans
0.34%
Inst Own
50.45%
Inst Trans
7.96%
ROA
-109.49%
ROE
-139.63%
ROIC
-131.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
21.71%
SMA50
6.21%
SMA200
-17.62%
Trades
Shs Outstand
103.88M
Shs Float
48.00M
52W High
6.42 -51.71%
52W Low
1.91 61.88%
Volatility
9.46% 10.44%
ATR (14)
0.27
RSI (14)
61.17
Beta
0.67
Rel Volume
0.04
Avg Volume
1.32M
Volume
2,317
Perf Week
22.53%
Perf Month
56.17%
Perf Quarter
-23.65%
Perf Half Y
-4.32%
Perf YTD
-18.64%
Perf Year
-8.28%
Perf 3Y
0.32%
Perf 5Y
-70.05%
Perf 10Y
-92.64%
Prev Close
3.02
Price
3.10
Change %
2.65%
Consensus
Strong Buy
Avg. Price Target
$15.43
Implied Upside
+397.7%
Analysts11incl. previous ratings
Rating Distribution10 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 14, 2026Resumed
LLeerink Partners
Outperform$13+319.4%
Jul 02, 2026Resumed
HH.C. Wainwright
Buy$10+222.6%
May 27, 2026Initiated
JPM logoJJP Morgan
Overweight$9+190.3%
Jan 29, 2025Initiated
TFC logoTTruist
Buy$18+480.6%
Oct 16, 2024Initiated
OPY logoOOppenheimer
Outperform$26+738.7%
Oct 03, 2024Initiated
WWedbush
Outperform$22+609.7%
Oct 02, 2024Initiated
HH.C. Wainwright
Buy$15+383.9%
Sep 04, 2024Initiated
RRobert W. Baird
Outperform$16+416.1%
Apr 03, 2024Initiated
LLeerink Partners
Outperform$25+706.5%
Nov 17, 2023Upgrade
C logoCCitigroup
Neutral → Buy$4.50+45.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hamilton Thomas EdwardDirectorNov 12 '26Buy2.6770,000187,08270,000Nov 12 09:32 PM
BEN-MAIMON CAROLEPresident and CEONov 11 '26Buy2.7718,05049,953386,326Nov 12 06:02 PM
THOMAS FRANK EDirectorNov 11 '26Buy2.738,00021,80015,000Nov 12 06:01 PM
Truitt JosephDirectorNov 11 '26Buy2.803,5009,7926,250Nov 12 06:00 PM
Harlow John B. Jr.President and COONov 11 '26Buy2.8017,80049,91867,800Nov 12 06:00 PM
Celano MichaelChief Financial OfficerNov 11 '26Buy2.7118,46049,992234,245Nov 12 05:56 PM
Shankar GopiChief Development OfficerNov 11 '26Buy2.715,00013,54981,443Nov 12 05:55 PM
Hamilton Thomas EdwardDirectorJul 06 '26Buy3.3450,000166,890714,798Jul 08 04:05 PM
Flynn James EDirectorFeb 27 '26Buy5.005,000,00025,000,00010,622,957Mar 02 07:46 PM
Hamilton Thomas EdwardDirectorFeb 27 '26Buy5.00100,000500,000664,798Mar 02 04:30 PM
THOMAS FRANK EDirectorFeb 27 '26Buy5.005,00025,0007,000Mar 02 04:30 PM
SHERMAN JEFFREY WDirectorFeb 27 '26Buy5.005,00025,0005,000Mar 02 04:30 PM
Larimar Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing treatments for patients suffering from complex rare diseases using a novel cell penetrating peptide technology platform. It also engages in the research, development, and commercialization of novel therapeutics for mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.
CEO & DirectorDr. Carole S. Ben-Maimon M.D.
Secretary & CFOMr. Michael Celano CPA
Ph.D.Dr. Gopi Shankar M.B.A.
President & COOMr. John B. Harlow Jr.
Vice President of Finance & AdministrationMr. John Berman